Pictured: Isabelle Rivière, Michel Sadelain & Renier Brentjens
In the Clinic
By Jim Stallard, MA, Writer/Editor  |  Wednesday, March 20, 2013

Memorial Sloan-Kettering researchers have used genetically modified immune cells to eradicate cancer in five patients with acute lymphoblastic leukemia.

Pictured: Isabelle Rivière and Michel Sadelain
In the Clinic
By Julie Grisham, MS, Science Writer/Editor  |  Monday, July 16, 2012

Memorial Sloan-Kettering’s trial to evaluate a new therapy for patients with beta-thalassemia is the first to receive FDA approval to treat this disease with genetically engineered cells.

Pictured: Isabelle Rivière, Michel Sadelain & Renier Brentjens
Feature
By Julie Grisham, MS, Science Writer/Editor  |  Wednesday, December 28, 2011

Years of innovative research, technology development, and facility expansion at Memorial Sloan-Kettering have led to several new experimental treatments for people with cancer.

Center News

Subscribe to Our E-newsletter

Get the latest information about cancer care.